

PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

: Brader, et al. Applicants

: 08/484,542 Serial No.

: 7 June 1995 Filed

1813

: Stabilized Acylated Insulin For

Examiner: Formulations Prickril

: 10361.49950 Docket No.

DECLARATION UNDER 37 C.F.R. 1.131

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

BEST AVAILABLE COPY

Group Art Unit:

I, Michael J. Beckage, declare that:

I am a co-inventor and an applicant in this application.

Attached exhibits 1, 2, and 3 are copies of pages from my notebook in which I recorded the preparation of a formulation comprising an aqueous solution of a fatty acid-acylated insulin and approximately 0.35 mole of zinc per mole of said fatty acidacylated insulin, and having a pH of approximately 7.5. The fatty-acid acylated insulin was N^{ϵ} -Lys^{B29}-palmitoyl-human insulin, which is referred to as C16-insulin. The formulation also contained m-cresol, a phenolic compound, at a concentration of approximately 2.5 mg/mL. The dates have been redacted.

All the actions, events, and observations described in this declaration occurred in the United States, prior to 23 March 1995.

I further declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or

imprisonment, or both (18 U.S.C. 1001), and may jeopardize the validity of the application or any patent issuing thereon.

BEST AVAILABLE COPY



